GEP20146064B - 3-minocyclopentanecarboxamides as chemokine receptor modulators - Google Patents
3-minocyclopentanecarboxamides as chemokine receptor modulatorsInfo
- Publication number
- GEP20146064B GEP20146064B GEAP200912239A GEAP2009012239A GEP20146064B GE P20146064 B GEP20146064 B GE P20146064B GE AP200912239 A GEAP200912239 A GE AP200912239A GE AP2009012239 A GEAP2009012239 A GE AP2009012239A GE P20146064 B GEP20146064 B GE P20146064B
- Authority
- GE
- Georgia
- Prior art keywords
- chemokine receptor
- minocyclopentanecarboxamides
- receptor modulators
- ted
- atherosclerosis
- Prior art date
Links
- 102000009410 Chemokine receptor Human genes 0.000 title abstract 2
- 108050000299 Chemokine receptor Proteins 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11805308P | 2008-11-26 | 2008-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20146064B true GEP20146064B (en) | 2014-03-25 |
Family
ID=41693100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP200912239A GEP20146064B (en) | 2008-11-26 | 2009-11-20 | 3-minocyclopentanecarboxamides as chemokine receptor modulators |
Country Status (38)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0920936A2 (pt) * | 2008-11-26 | 2020-08-11 | Pfizer Inc | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas |
| KR101303963B1 (ko) * | 2011-04-08 | 2013-09-05 | 재단법인 경기과학기술진흥원 | (1ｒ,2ｒ,3ｒ)-3-아미노사이클로펜탄-1,2-디올을 포함하는 항알러지용 조성물 |
| KR102456088B1 (ko) | 2014-04-04 | 2022-10-19 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| TW201605451A (zh) * | 2014-07-17 | 2016-02-16 | 參天製藥股份有限公司 | 老年性黃斑部病變之預防或治療劑 |
| JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
| TWI830733B (zh) * | 2018-05-11 | 2024-02-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | 環戊烷化合物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| ATE237342T1 (de) | 1994-07-11 | 2003-05-15 | Athena Neurosciences Inc | Inhibitoren der leukozytenadhäsion |
| US5462208A (en) | 1994-08-01 | 1995-10-31 | The Procter & Gamble Company | Two-phase dispensing systems utilizing bellows pumps |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| AU5259296A (en) | 1995-04-07 | 1996-10-23 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of athero sclerosis |
| US5704960A (en) | 1995-12-20 | 1998-01-06 | Corning, Inc. | Method of forming an optical fiber for reduced polarization effects in amplifiers |
| GB9603741D0 (en) | 1996-02-22 | 1996-04-24 | Lin Mei | Treatment of water by electrolysis |
| US6281212B1 (en) | 1996-07-12 | 2001-08-28 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
| EP1017382B1 (en) | 1997-05-29 | 2006-03-01 | Merck & Co., Inc. (a New Jersey corp.) | Biarylalkanoic acids as cell adhesion inhibitors |
| JP2002512625A (ja) | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としての複素環アミド化合物 |
| WO1998053818A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
| AU7667498A (en) | 1997-05-30 | 1998-12-30 | Celltech Therapeutics Limited | Anti-inflammatory tyrosine derivatives |
| ES2206953T3 (es) | 1997-06-23 | 2004-05-16 | Tanabe Seiyaku Co., Ltd. | Inhibidores de la adherencia celular mediada por alfa 4-beta 1. |
| US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| MY129850A (en) * | 2002-04-29 | 2007-05-31 | Merck Sharp & Dohme | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| SI1501507T1 (sl) * | 2002-04-29 | 2008-12-31 | Merck & Co Inc | Tetrahidropiranil ciklopentil tetrahidropiridopiridin modulatorji s kemokinsko receptorsko aktivnostjo |
| MXPA06007000A (es) * | 2003-12-18 | 2006-08-31 | Incyte Corp | Derivados de 3-cicloalquilaminopirrolidina como moduladores de receptores de quimiocina. |
| US7435830B2 (en) * | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| US7566726B2 (en) | 2004-04-28 | 2009-07-28 | Merck & Co. Inc. | 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity |
| WO2006004741A2 (en) * | 2004-06-28 | 2006-01-12 | Incyte Corporation | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
| CN1976702A (zh) * | 2004-06-28 | 2007-06-06 | 因赛特公司 | 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类 |
| GEP20094843B (en) * | 2004-06-28 | 2009-11-25 | Incyte Corp | 3-aminocyclopentane carboxamides as modulators of chemokine receptors |
| MEP1008A (xx) | 2005-12-21 | 2010-02-10 | Incyte Corp | 3-aminociklopentankarboksamidi kao modulatori receptora hemokina |
| BRPI0920936A2 (pt) * | 2008-11-26 | 2020-08-11 | Pfizer Inc | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas |
-
2009
- 2009-11-20 BR BRPI0920936-0A patent/BRPI0920936A2/pt not_active Application Discontinuation
- 2009-11-20 ES ES09774939T patent/ES2415430T3/es active Active
- 2009-11-20 EA EA201170721A patent/EA020470B1/ru not_active IP Right Cessation
- 2009-11-20 ME MEP-2011-83A patent/ME01144B/me unknown
- 2009-11-20 AU AU2009321221A patent/AU2009321221B2/en not_active Ceased
- 2009-11-20 MY MYPI20112377 patent/MY152557A/en unknown
- 2009-11-20 DK DK09774939.4T patent/DK2370442T5/da active
- 2009-11-20 KR KR1020117011887A patent/KR101374412B1/ko not_active Expired - Fee Related
- 2009-11-20 GE GEAP200912239A patent/GEP20146064B/en unknown
- 2009-11-20 HR HRP20130409AT patent/HRP20130409T2/hr unknown
- 2009-11-20 PL PL09774939T patent/PL2370442T3/pl unknown
- 2009-11-20 PT PT97749394T patent/PT2370442E/pt unknown
- 2009-11-20 SI SI200930601T patent/SI2370442T1/sl unknown
- 2009-11-20 CN CN200980147183.7A patent/CN102227429B/zh not_active Expired - Fee Related
- 2009-11-20 UA UAA201106571A patent/UA99978C2/uk unknown
- 2009-11-20 CA CA2743030A patent/CA2743030C/en not_active Expired - Fee Related
- 2009-11-20 PE PE2011001105A patent/PE20110831A1/es active IP Right Grant
- 2009-11-20 RS RS20130260A patent/RS52810B9/sr unknown
- 2009-11-20 WO PCT/IB2009/055232 patent/WO2010061329A1/en not_active Ceased
- 2009-11-20 RS RS20130260D patent/RS52810B8/sr unknown
- 2009-11-20 NZ NZ592919A patent/NZ592919A/xx not_active IP Right Cessation
- 2009-11-20 MX MX2011005526A patent/MX2011005526A/es active IP Right Grant
- 2009-11-20 AP AP2011005732A patent/AP3113A/xx active
- 2009-11-20 EP EP09774939.4A patent/EP2370442B9/en active Active
- 2009-11-20 JP JP2011538083A patent/JP5108153B2/ja active Active
-
2010
- 2010-06-07 US US12/795,266 patent/US8293903B2/en active Active
-
2011
- 2011-05-05 IL IL212732A patent/IL212732A/en active IP Right Grant
- 2011-05-18 TN TN2011000254A patent/TN2011000254A1/fr unknown
- 2011-05-24 CO CO11064157A patent/CO6361921A2/es active IP Right Grant
- 2011-05-24 NI NI201100102A patent/NI201100102A/es unknown
- 2011-05-25 DO DO2011000154A patent/DOP2011000154A/es unknown
- 2011-05-25 CL CL2011001223A patent/CL2011001223A1/es unknown
- 2011-05-25 EC EC2011011081A patent/ECSP11011081A/es unknown
- 2011-05-26 CU CU2011000121A patent/CU24022B1/es active IP Right Grant
- 2011-05-26 CR CR20110275A patent/CR20110275A/es unknown
- 2011-05-26 MA MA33895A patent/MA32834B1/fr unknown
- 2011-05-26 SV SV2011003923A patent/SV2011003923A/es unknown
- 2011-06-01 ZA ZA2011/04069A patent/ZA201104069B/en unknown
-
2012
- 2012-09-14 US US13/616,375 patent/US8946413B2/en active Active
-
2013
- 2013-05-29 CY CY20131100427T patent/CY1114020T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200806300A (en) | New therapeutic combinations for the treatment of depression | |
| GEP20125704B (en) | Plk kinase inhibitors | |
| MX2009011997A (es) | Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos. | |
| GEAP202115057A (en) | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | |
| TW200738242A (en) | Dihydropteridinones in the treatment of respiratory diseases | |
| NZ612000A (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
| GEP20125666B (en) | HYDROXYMETHYL PYRROLIDINES AS β3 ADRENERGIC RECEPTOR AGONISTS | |
| MX2010009022A (es) | Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso. | |
| GEP20156368B (en) | Non-nucleoside reverse transcriptase inhibitors | |
| GEP20186838B (en) | 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors | |
| TW200833328A (en) | 2-aza-bicyclo[3.1.0]hexane derivatives | |
| GEP20156351B (en) | Glucagon receptor modulator | |
| TW200716628A (en) | Novel compounds | |
| MX2007003546A (es) | Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa. | |
| GB0625648D0 (en) | Compounds | |
| MX2009011578A (es) | 6-fenilpirimidinonas como moduladores de pim. | |
| MX2011006843A (es) | Dihidropiridona-amidas como moduladores de p2x7. | |
| GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| GEP20146064B (en) | 3-minocyclopentanecarboxamides as chemokine receptor modulators | |
| TW200722081A (en) | New therapeutic combinations for the treatment or prevention of depression | |
| MX2010009395A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos. | |
| GEP20135927B (en) | 1-benzyl-3-hydroxymethylindaz-ole derivatives and usage thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression | |
| MX2010006204A (es) | Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| CY1115725T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων | |
| MX2009013501A (es) | Compuestos piperidinicos y sus usos. |